Valion Bio, Inc. - Common stock (VBIO)
Investment Snapshot
- Piotroski F-Score 2/9 — signs of financial weakness
- Negative net margin (-2,857.7%) — currently unprofitable
- Revenue declining 34% annually
Valion Bio, Inc. - Common stock (VBIO) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $3 million . Key value metrics: Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Valion Bio, Inc. - Common stock — Fundamental Analysis Summary
StockPik's composite Value Score for VBIO is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
VBIO reports a thin gross margin of 0.7% and a negative operating margin of -2,700.2%.
VBIO shows revenue declining at 34% year-over-year, with earnings declining at 57%.